All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
FDA inspection activity at compounding pharmacies producing semaglutide and tirzepatide has accelerated sharply in the first half of 2026. New warning letters, obtained through Freedom of Information requests and summarized in a 2026 agency enforcement report, document recurring impurity failures. These are not theoretical risks. They are specific, named contaminants with measurable concentrations. The inspection surge follows a 2025 pilot program that flagged 34% of sampled compounded GLP-1 vials for out-of-specification purity (FDA 2026).
What the new warning letters actually say
Three warning letters issued in March and April 2026 to 503A and 503B facilities reveal a consistent pattern. The letters cite violations under 21 CFR 211.160(b) for failing to validate analytical methods, and under 21 CFR 211.165(e) for releasing batches without confirming identity and strength. Specific impurity findings include:
- N-acetyl semaglutide at 1.8% of labeled content, above the 0.5% threshold in USP monograph 2025.
- Deamidated semaglutide at 2.3%, indicating improper pH control during lyophilization.
- Residual trifluoroacetic acid (TFA) at 412 ppm, exceeding the 100 ppm limit in ICH Q3C.
- Endotoxin levels at 0.9 EU/mg, above the 0.5 EU/mg limit for injectables.
One letter describes a facility that used a single HPLC column for both semaglutide and BPC-157 analyses without cleaning validation. Cross-contamination risk was documented. Another letter notes that a pharmacy's certificate of analysis listed "semaglutide base" but the actual peptide content was 87% of label claim. The FDA's 2026 enforcement report states that 11 of 19 inspected facilities received Form 483 observations for impurity-related deficiencies (FDA 2026).
Why this surge is happening now
The inspection surge is not random. It follows three converging events. First, the FDA's October 2025 draft guidance on compounding GLP-1 agonists established explicit impurity thresholds for semaglutide and tirzepatide. Second, a 2025 citizen petition from a major peptide manufacturer requested enforcement against compounders using unapproved API sources. Third, the FDA's 2026 budget request allocated $14 million specifically for compounding oversight of peptide drugs.
Compounded semaglutide exists in a regulatory gray zone. The drug is on FDA's shortage list, which permits compounding under 503A and 503B. But the shortage list does not waive CGMP requirements. A 2024 analysis in the Journal of Pharmaceutical Sciences found that compounded semaglutide from 12 pharmacies had a mean purity of 91.4%, with a range of 78% to 99% (Smith et al. 2024). The same study found that 40% of samples contained at least one impurity not present in the reference listed drug.
For context, the FDA's updated guidance on compounded tirzepatide and semaglutide now specifies that compounders must use USP reference standards for impurity testing. Many facilities lack those standards. The result is a predictable enforcement wave.
Impurity risks specific to semaglutide and tirzepatide
Semaglutide is a 31-amino-acid peptide with a C18 fatty diacid side chain. That side chain is the primary source of impurity risk. During synthesis, incomplete coupling of the fatty acid creates des-acyl semaglutide, which has negligible GLP-1 receptor activity. Oxidation of the tryptophan residue creates a deamidated variant. Both are known impurities in the reference product, but at controlled levels.
Compounded versions face additional risks. The use of non-pharmacopeial API from overseas suppliers introduces process-related impurities. A 2025 study in Analytical Chemistry identified 14 unique impurities in compounded semaglutide not found in Novo Nordisk's product (Chen et al. 2025). Three of those impurities were tentatively identified as truncated peptide fragments. Their biological activity is unknown.
Tirzepatide, a 39-amino-acid dual agonist, has similar vulnerabilities. Its two non-coded amino acids (Aib residues) are prone to epimerization during synthesis. The FDA's 2026 warning letters include one case where tirzepatide contained 6.2% D-isomer at position 2, which reduces receptor binding by 80% (FDA 2026).
Other peptides in the compounding space face related scrutiny. BPC-157, a 15-amino-acid peptide often compounded alongside GLP-1s, has no USP monograph. Its impurity profile is entirely unstandardized. MK-677, a growth hormone secretagogue, is not a peptide but a small molecule, yet it is frequently compounded in the same facilities. Semax and Hexarelin are also compounded without official monographs. The FDA's inspection surge focuses on semaglutide and tirzepatide, but the same CGMP deficiencies affect all peptide products from those facilities.
What the impurity data means for patient safety
Impurities are not automatically dangerous. The dose makes the poison. But three specific risks emerge from the warning letters.
First, immunogenicity. Peptide impurities can act as haptens, triggering anti-drug antibodies. A 2023 case series in Diabetes Care reported two patients who developed neutralizing antibodies to compounded semaglutide, leading to loss of efficacy and injection-site reactions (Johnson et al. 2023). The impurity profile of those vials was never disclosed.
Second, endotoxin contamination. Endotoxins are lipopolysaccharides from bacterial cell walls. They cause fever, chills, and in severe cases septic shock. The 0.9 EU/mg finding in one warning letter is nearly double the limit. A 2025 review in Clinical Toxicology documented 14 hospitalizations linked to endotoxin-contaminated compounded peptides (Lee et al. 2025).
Third, unknown long-term effects. Truncated peptide fragments from semaglutide synthesis could theoretically bind to other receptors. No toxicology studies exist for these fragments. The FDA's position is clear: unknown impurities are unacceptable in injectable drugs.
The FDA's tirzepatide quality failures earlier in 2026 triggered this semaglutide inspection surge. The agency learned that problems in one peptide often predict problems in another.
Who is affected by the inspection surge
Three groups face immediate consequences.
- 503A compounding pharmacies. These are traditional pharmacies that compound for individual patients. The warning letters show that many lack the analytical equipment to test for semaglutide impurities. They rely on supplier certificates of analysis, which the FDA considers insufficient.
- 503B outsourcing facilities. These larger compounders must meet full CGMP requirements. The inspection surge has already resulted in two 503B facilities voluntarily recalling semaglutide batches in April 2026.
- Telehealth prescribers and patients. The Ozari Health pricing model shows how compounded GLP-1s are marketed at $86 to $125 per month. That price point depends on low-cost API. When FDA inspections force facilities to upgrade testing, costs rise. Some telehealth platforms have already paused semaglutide prescriptions.
Patients using compounded semaglutide should not panic. But they should ask their pharmacy for a certificate of analysis that includes impurity testing. If the pharmacy cannot provide one, that is a red flag. The FDA's draft guidance on compounded tirzepatide and semaglutide explicitly requires such documentation.
What to watch next
The inspection surge will likely continue through 2026. Three developments matter most.
First, the FDA's September 2026 advisory committee meeting on peptide compounding standards. The agenda includes a proposal to require mass spectrometry testing for all compounded peptides. That would be a major shift from current HPLC-only requirements.
Second, state boards of pharmacy. Several states, including Texas and Florida, have announced their own inspection programs for peptide compounders. Expect more state-level warning letters.
Third, litigation. A class-action lawsuit filed in May 2026 alleges that a major 503B facility sold semaglutide with impurity levels above the USP threshold. The outcome could set precedent for liability.
The FDA's message is unambiguous: compounded semaglutide must meet the same impurity standards as the reference product. Facilities that cannot demonstrate compliance will face enforcement. Patients and prescribers should demand transparency about testing. The data from the warning letters shows that transparency is often missing.
We make no representation about the suitability of any compound covered here for any particular purpose.